

IP Lab

February 19, 2009

GENERIC'S ENVY, PATENT OWNER'S PRIDE: ROCHE'S 'VALCYTE' TRIUMPHS AT THE CHENNAI PATENT OFFICE

Dear All,

On January 1, 2005, the product patent regime in India was born again. In these few years of product patent regime, the Indian pharmaceutical industry has witnessed some tough battles in Indian courts and the four Patent Offices, between MNC patent holders and Indian generic drug manufacturers.

Roche's drug "**Valcyte**" (Valganciclovir hydrochloride) too has faced legal challenges. It met its pre-grant stage challenge in which it recently tasted victory at Chennai Patent Office, and is now facing post grant challenge. Roche has instituted infringement action against Cipla and is awaiting its hearing.

Please [click here for the document](#) tracing the journey of Valcyte in India and the hurdles it has met and will meet to survive as a valid patent in India.

IP-Pharma Team

Aditi Nadkarni / Gowree Gokhale

DISCLAIMER

The contents of this hotline should not be construed as legal opinion. View detailed disclaimer.

This Hotline provides general information existing at the time of preparation. The Hotline is intended as a news update and Nishith Desai Associates neither assumes nor accepts any responsibility for any loss arising to any person acting or refraining from acting as a result of any material contained in this Hotline. It is recommended that professional advice be taken based on the specific facts and circumstances. This Hotline does not substitute the need to refer to the original pronouncements.

This is not a Spam mail. You have received this mail because you have either requested for it or someone must have suggested your name. Since India has no anti-spamming law, we refer to the US directive, which states that a mail cannot be considered Spam if it contains the sender's contact information, which this mail does. In case this mail doesn't concern you, please unsubscribe from mailing list.

Research Papers

Fintech

May 05, 2025

Medical Device Industry in India

April 28, 2025

Clinical Trials and Biomedical Research in India

April 22, 2025

Research Articles

2025 Watchlist: Life Sciences Sector India

April 04, 2025

Re-Evaluating Press Note 3 Of 2020: Should India's Land Borders Still Define Foreign Investment Boundaries?

February 04, 2025

INDIA 2025: The Emerging Powerhouse for Private Equity and M&A Deals

January 15, 2025

Audio

CCI's Deal Value Test

February 22, 2025

Securities Market Regulator's Continued Quest Against "Unfiltered" Financial Advice

December 18, 2024

Digital Lending - Part 1 - What's New with NBFC P2Ps

November 19, 2024

NDA Connect

Connect with us at events, conferences and seminars.

NDA Hotline

[Click here to view Hotline archives.](#)

Video

Vyapak Desai speaking on the danger of deepfakes | Legally Speaking with Tarun Nangia | NewsX

April 01, 2025

**SIAC 2025 Rules: Key changes &
Implications**

February 18, 2025

